Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 803-810

  Kutala, Blaise K ^a,b   Guedj, Jeremie ^a   Asselah, Tarik ^b   Boyer, Nathalie ^b   Mouri, Feryel ^b   Martinot Peignoux, Michelle ^b   Valla, Dominique ^b   Marcellin, Patrick ^b   Duval, Xavier ^a,c  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b BEAUJON HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CHILD PUGH SCORE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; DRUG EFFECTS; HEPACIVIRUS; LIVER DISEASES; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HUMANS; INTERFERONS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84921789702     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04027-14     Document Type: Article

References (26)

1. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29(Suppl 1):S74-S81. http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538. http: //dx.doi.org/10.1016/j.jhep.2006.05.013.
3. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. 2006. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43:1303-1310. http://dx.doi.org/10.1002/hep .21176.
4. D'Amico G, Garcia-Tsao G, Pagliaro L. 2006. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217-231. http://dx.doi.org/10.1016/j.jhep.2005.10.013.
5. Marcellin P, Asselah T, Boyer N. 2002. Fibrosis and disease progression in hepatitis C. Hepatology 36: S47-S56. http://dx.doi.org/10.1002/hep .1840360707.
6. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. 2009. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 39:432-438. http://dx.doi.org/10.1111/j.1872-034X.2008.00477.x.
7. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. 2002. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483-491. http://dx.doi.org/10.1053/gast.2002.34785.
8. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. 2007. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147:677-684. http://dx.doi.org/10.7326/0003-4819-147-10-200711200-00003.
9. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL, Italian Association of the Study of the Liver Disease (AISF). 2007. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45:579-587. http://dx.doi.org /10.1002/hep.21492.
10. Pereira OC, Feld JJ. 2013. Editorial commentary: sustained virologic response for patients with hepatitis C-related cirrhosis: a major milestone, but not quite a cure. Clin Infect Dis 57:237-239. http://dx.doi.org/10.1093 /cid/cit237.
11. D'Ambrosio R, Aghemo A. 2012. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 12:361-368. http: //dx.doi.org/10.5812/hepatmon.6095.
12. Vezali E, Aghemo A, Colombo M. 2010. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 32:2117-2138. http://dx.doi.org/10.1016/S0149-2918(11)00022-1.
13. Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. 2013. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol 58:452-459. http://dx.doi.org/10.1016/j .jhep.2012.11.001.
14. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. 2012. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2593. http://dx.doi.org/10.1001/jama.2012.144878.
15. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stal P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. 2013. A risk for hepatocellular carcinoma persists longterm after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57:230-236. http://dx.doi.org/10 .1093/cid/cit234.
16. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M, Tokyo-Chiba Hepatitis Research Group. 2005. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142:105-114. http: //dx.doi.org/10.7326/0003-4819-142-2-200501180-00009.
17. Martens EP, de Boer A, Pestman WR, Belitser SV, Stricker BH, Klungel OH. 2008. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiol Drug Saf 17:1-8. http://dx.doi.org/10.1002/pds.1520.
18. Rubin DB. 2004. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 13:855-857. http://dx.doi.org/10 .1002/pds.968.
19. Rosenbaum PR. 1984. Reducing bias in observational studies using subclassification on the propensity score. JAMA 387:9.
20. Imazeki F, Yokosuka O, Fukai K, Saisho H. 2003. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 38:493-502. http://dx.doi.org/10.1053/jhep.2003.50329.
21. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N. 2004. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 11: 148 -156. http://dx.doi.org/10.1046/j.1365-28 93.2003.00481.x.
22. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. 2010. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitisCpatients with advanced fibrosis. J Hepatol 52:652-657. http://dx.doi.org/10.1016/j.jhep.2009.12.028.
23. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, HALT-C Trial Investigators. 2008. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429-2441. http://dx.doi.org/10.1056 /NEJMoa0707615.
24. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, O'Farrelly C. 2011. Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 6:e27866. http://dx.doi.org/10.1371/journal.pone .0027866.
25. Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. 1999. Effects of interferon therapy in "non responder" patients with chronic hepatitis C. J Hepatol 31(Suppl 1):S178-S183.
26. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, HALT-C Trial Group. 2010. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52:833-844. http://dx.doi.org/10.1002/hep.23744.